AstraZeneca (LSE:AZN) has received approval from the U.S. Food and Drug Administration for Calquence (acalabrutinib) in combination with venetoclax as the first fully oral, fixed-duration treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The 14-month regimen offers a defined course of therapy, providing an alternative to indefinite treatment and enabling clinicians to tailor care to individual patient preferences and clinical needs.
The decision is supported by data from the Phase III AMPLIFY trial, in which the Calquence–venetoclax combination demonstrated a statistically significant improvement in progression-free survival compared with standard chemoimmunotherapy. At the three-year mark, 77% of patients receiving the combination remained progression-free, versus 67% in the chemotherapy arm. The safety profile was consistent with prior experience of Calquence. The regimen has already been authorised in Europe, Canada, the U.K. and other markets, reinforcing AstraZeneca’s position in the first-line CLL setting.
Beyond CLL, the company continues to evaluate Calquence both as monotherapy and in combination regimens across a range of B-cell malignancies, including mantle cell lymphoma and diffuse large B-cell lymphoma. The expanded U.S. label, alongside ongoing global regulatory activity, supports AstraZeneca’s ambition to strengthen its haematology franchise and broaden adoption of its BTK inhibitor-based therapies in a sizable and growing patient population.
From an investment perspective, the company’s outlook remains underpinned by solid operational performance, earnings growth guidance and continued pipeline advancement. However, valuation metrics — including a price-to-earnings ratio around 30 — and variability in recent free cash flow temper the picture. Technical indicators suggest the shares remain in an overall uptrend, though momentum appears somewhat stretched.
More about AstraZeneca
AstraZeneca is a global, science-driven biopharmaceutical group headquartered in Cambridge, U.K. The company focuses on developing and commercialising prescription medicines across oncology, rare diseases and biopharmaceuticals, spanning cardiovascular, renal and metabolism, as well as respiratory and immunology. Its oncology and haematology portfolio has been strengthened through acquisitions including Alexion and Gracell Biotechnologies, with medicines marketed in more than 125 countries worldwide.
Leave a Reply